Loading Events

Team Leader, Oncology, APJ Illumina

Comprehensive Genomic Profiling plus the detection of Homologous Recombination Deficiency (HRD) with a gold-standard assay

Dr Joel Goeghegan will discuss the technology and application of Illumina’s latest addition to the TSO-500 assay, the Homologous Recombination Deficiency (HRD) score and will show that the accurate assessment of HRD via NGS requires analysis for mutations in causal genes (such as BRCA1/2 and others) as well as ‘genomic scars’ including Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI) and Large Scale Transitions (LST), rather than just LOH alone, whereby a significant percentage of tumours would be missed.

HRD is particularly prevalent in ovarian, breast, prostate and pancreatic tumours and is an important biomarker for PARP inhibitors.

This event will be held online via Zoom. Registrations essential.

Register for this event


Share This Story, Choose Your Platform!